Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, Das A, Hartley L, Stranges S. Mediterranean-Style diet for the primary and secondary prevention of cardiovascular disease: a Cochrane Review. Glob Heart. 2020 Aug 12;15(1):56. doi: 10.5334/gh.853
Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A. Multiple risk factor interventions for primary prevention of CVD in LMIC: a Cochrane review. Glob Heart. 2017 Sep;12(3):199-208.e. doi: 10.1016/j.gheart.2016.03.639
Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, He Z. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 2016 Sep 14;16(9):5401-8. doi: 10.1021/acs.nanolett.6b01632
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Frye S, Crosby M, Edwards TP, Juliano R. US academic drug discovery. Nat Rev Drug Discov. 2011 Jun 1;10(6):409-10. doi: 10.1038/nrd3462
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Nicholls TJ, Cook DJ, Rogers DJ, Wolowacz SE, Smart JD. An investigation of lectin toxicity with cultured human conjunctival epithelial cells; lectins: biology biochemistry. Clin Chem. 1996;11:273-6.